The clinical information you need, at your fingertips.

A 14-protein plasma signature identified future lung cancer more than five years out and singled out the patients who would most benefit from anti-inflammatory prevention. . .

Phase 3 results show benefits of finerenone in a large underserved chronic kidney disease population previously lacking evidence-based options. . .

Observational data suggest dihydropyridine calcium-channel blockers may increase CKD progression risk despite background RAS and SGLT2 inhibitor therapy. . .

Patients reported better physical functioning and overall well-being, equivalent to approximately eight additional days in full health per year. . .

In older patients ineligible for intensive chemo, an all-oral two-pill regimen produced a complete response in nearly half and survival comparable to IV standard care. . .

Results support moving PARP inhibition into the hormone-sensitive setting for patients with HRR gene alterations. . .